search
Back to results

Allogeneic Mesenchymal Stem Cells for Osteoarthritis

Primary Purpose

Osteoarthritis of Knee Joint

Status
Completed
Phase
Phase 2
Locations
Malaysia
Study Type
Interventional
Intervention
Ex- vivo cultured adult allogeneic MSCs
Plasmalyte-A
Sponsored by
Stempeutics Research Pvt Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis of Knee Joint focused on measuring Osteoarthritis, Knee, Stem cell, MSC

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Males or females in the age 20 - 70 years (both inclusive)
  2. Radiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic entry criteria.
  3. History of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics.
  4. Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs.
  5. Patients who have been on stable medication for the past three months.
  6. Patients who have not received intra articular steroids or hyaluronan within the last three months.
  7. Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study
  8. Ability to provide written informed consent.

Exclusion Criteria:

  1. Prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.
  2. History of surgery, including arthroscopy, or major trauma to the study joint in the previous 12 months
  3. Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination
  4. Infections in or around the knee.
  5. Patients awaiting a replacement knee or hip joint
  6. Patients with other conditions that cause pain
  7. Significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices
  8. Patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis
  9. Other pathologic lesions on x-rays of knee
  10. Positive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or VDRL
  11. History of Bleeding disorders
  12. Known hypersensitivity to Hyaluronan products or animal sera
  13. For women of child-bearing potential: positive pregnancy test or lactating

Sites / Locations

  • Pantai Cheras Medical Centre
  • Serdang Hospital
  • KPJ Ampang Puteri Specialist Hospital
  • Selayang Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ex- vivo cultured adult allogeneic MSCs

Plasmalyte-A

Arm Description

Single intraarticular dose of allogeneic MSCs

Single intraarticular dose of 2ml Plasmalyte

Outcomes

Primary Outcome Measures

Number and percentage of patients with adverse events as a measure of safety and tolerability
Safety evaluation will include assessment of physical examination, periodic monitoring of vital signs (heart rate, respiratory rate, blood pressure and temperature), clinical laboratory investigations (including haematology, serum chemistry, LFT, urine-analysis) and 12-lead ECG recording. Tolerability: Adverse events monitored using information volunteered by the patients and as observed by the PI will be summarized descriptively by total number of AE(s) and compared between the study arms.

Secondary Outcome Measures

Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score
Change from baseline in WOMAC OA stiffness index
Change from baseline in WOMAC OA composite index
Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)
Change from baseline in radiographic (X-ray) findings of knee
Change from baseline in the WORMS score of knee using MRI
Change from baseline in arthritis pain scores on the visual analogue scale
Reduction in the intake of analgesic tablets from baseline

Full Information

First Posted
September 20, 2011
Last Updated
May 11, 2016
Sponsor
Stempeutics Research Pvt Ltd
Collaborators
Stempeutics Research Malaysia SDN BHD
search

1. Study Identification

Unique Protocol Identification Number
NCT01448434
Brief Title
Allogeneic Mesenchymal Stem Cells for Osteoarthritis
Official Title
A Randomized, Double Blind, Multicentric, Placebo Controlled, Phase -II Study Assessing the Safety and Efficacy of Intraarticular Ex-vivo Cultured Adult Allogeneic Mesenchymal Stem Cells in Patients With Osteoarthritis of Knee
Study Type
Interventional

2. Study Status

Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stempeutics Research Pvt Ltd
Collaborators
Stempeutics Research Malaysia SDN BHD

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed to know the safety and efficacy of 2 different doses of mesenchymal stem cells in patients suffering from osteoarthritis of knee joint.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of Knee Joint
Keywords
Osteoarthritis, Knee, Stem cell, MSC

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ex- vivo cultured adult allogeneic MSCs
Arm Type
Experimental
Arm Description
Single intraarticular dose of allogeneic MSCs
Arm Title
Plasmalyte-A
Arm Type
Placebo Comparator
Arm Description
Single intraarticular dose of 2ml Plasmalyte
Intervention Type
Biological
Intervention Name(s)
Ex- vivo cultured adult allogeneic MSCs
Intervention Description
Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
Intervention Type
Biological
Intervention Name(s)
Plasmalyte-A
Intervention Description
Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
Primary Outcome Measure Information:
Title
Number and percentage of patients with adverse events as a measure of safety and tolerability
Description
Safety evaluation will include assessment of physical examination, periodic monitoring of vital signs (heart rate, respiratory rate, blood pressure and temperature), clinical laboratory investigations (including haematology, serum chemistry, LFT, urine-analysis) and 12-lead ECG recording. Tolerability: Adverse events monitored using information volunteered by the patients and as observed by the PI will be summarized descriptively by total number of AE(s) and compared between the study arms.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Change from baseline in the WOMAC OA (Western Ontario and McMaster Universities Osteoarthritis) Index -pain subscale score
Time Frame
1 Year
Title
Change from baseline in WOMAC OA stiffness index
Time Frame
1 Year
Title
Change from baseline in WOMAC OA composite index
Time Frame
1 Year
Title
Change from baseline in ICOAP (Intermittent and Constant Osteoarthritis Pain)
Time Frame
1 Year
Title
Change from baseline in radiographic (X-ray) findings of knee
Time Frame
1 Year
Title
Change from baseline in the WORMS score of knee using MRI
Time Frame
1 Year
Title
Change from baseline in arthritis pain scores on the visual analogue scale
Time Frame
1 Year
Title
Reduction in the intake of analgesic tablets from baseline
Time Frame
1 Year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females in the age 20 - 70 years (both inclusive) Radiographic evidence of grade 2 to 3 osteoarthritis based on the Kellgren and Lawrence radiographic entry criteria. History of primary idiopathic osteoarthritis of the knee characterized by pain which requires intake of analgesics. Self-reported difficulty in at least one of the following activities attributed to knee pain: lifting and carrying groceries, walking 400 metres, getting in and out of a chair, or going up and down stairs. Patients who have been on stable medication for the past three months. Patients who have not received intra articular steroids or hyaluronan within the last three months. Female patients of childbearing age must be willing to use accepted methods of contraception during the course of the study Ability to provide written informed consent. Exclusion Criteria: Prior or ongoing medical conditions (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results. History of surgery, including arthroscopy, or major trauma to the study joint in the previous 12 months Signs of active study joint inflammation including redness, warmth, and/or, if qualifying with osteoarthritis of the knee, a large, bulging effusion of the study knee joint with the loss of normal contour of the joint at the screening visit or at the baseline examination Infections in or around the knee. Patients awaiting a replacement knee or hip joint Patients with other conditions that cause pain Significantly incapacitated or disabled and would be categorized as ACR Functional Class IV (largely or wholly incapacitated), or unable to walk without assistive devices Patients with other known rheumatic or inflammatory disease such as rheumatoid arthritis Other pathologic lesions on x-rays of knee Positive hepatitis B surface antigen, hepatitis C antibody test, Anti human immunodeficiency virus (HIV) antibody test, or VDRL History of Bleeding disorders Known hypersensitivity to Hyaluronan products or animal sera For women of child-bearing potential: positive pregnancy test or lactating
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prof. Dr. Muhammad Ali Noor Muhd Abdul Ghani, FRCS
Organizational Affiliation
KPJ Ampang Puteri Specialist Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Ahmad Hisham Abd. Rashid, MD., MS
Organizational Affiliation
Clinical Research Centre Hospital Serdang
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Suntharalingam Subramaniam, FRCS
Organizational Affiliation
Pantai Cheras Medical Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dato' Dr. Ramli Baba, MS
Organizational Affiliation
Selayang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pantai Cheras Medical Centre
City
Kuala Lumpur
State/Province
Federal territory
ZIP/Postal Code
56100
Country
Malaysia
Facility Name
Serdang Hospital
City
Kuala Lumpur
State/Province
Selangor
ZIP/Postal Code
43300
Country
Malaysia
Facility Name
KPJ Ampang Puteri Specialist Hospital
City
Kuala Lumpur
State/Province
Selangor
ZIP/Postal Code
68000
Country
Malaysia
Facility Name
Selayang Hospital
City
Kuala Lumpur
State/Province
Selangor
ZIP/Postal Code
68100
Country
Malaysia

12. IPD Sharing Statement

Learn more about this trial

Allogeneic Mesenchymal Stem Cells for Osteoarthritis

We'll reach out to this number within 24 hrs